Abstract
Purpose:
We investigated whether dietary carotenoids lutein and zeaxanthin (L/Z) in the serum and macula were associated with central retinal arteriole and venule calibers in a follow-up ancillary study among older women in the Women's Health Initiative.
Methods:
Among 390 women who participated in Carotenoids in Age-Related Eye Disease Study 2 (CAREDS2) (2016–2019), we investigated associations between serum L/Z at Women's Health Initiative baseline (1994–1998), and macular pigment optical density (MPOD) at CAREDS baseline (2001–2004), with central retinal vessel caliber in CAREDS2. MPOD was measured using heterochromatic flicker photometry (0.5° from the foveal center) in CAREDS baseline and CAREDS2. Vessel calibers were measured from fundus photographs (CAREDS2). We also explored associations in women with stable MPOD (±0.10 optical density units) over 15 years (n = 106), given the long-term increases in MPOD related to diet patterns and supplement use. Associations were investigated using linear modeling.
Results:
In the full sample (n = 390), higher serum L/Z (tertile 3 vs. 1) was positively associated with arteriole caliber (mean ± SE, 145.0 ± 1.4 µm vs. 140.8 ± 1.4 µm; P = 0.05) and venule caliber (214.6 ± 2.2 µm vs. 207.5 ± 2.2 µm; P = 0.03). MPOD was also associated with wider vessel calibers (tertile 3 vs. 1), but the trend was only statistically significant for venules (144.4 ± 1.4 µm vs. 141.1 ± 1.4 µm [P = 0.12] and 213.3 ± 2.1 µm vs. 206.0 ± 2.1 µm [P = 0.02], respectively.) Most associations were strengthened in women with stable MPOD over 15 years, including between MPOD and arteriole caliber (149.8 ± 2.6 µm vs.135.8 ± 3.0 µm; P = 0.001).
Conclusions:
Higher L/Z status in serum and retina was associated with larger central retinal vessel calibers. Prospective studies and clinical trials are needed to elucidate whether L/Z supplementation prevents vision loss through increasing blood flow.
Dietary carotenoids lutein and zeaxanthin (L/Z) have been associated with better vision and lower risks of age-related eye disease, especially for AMD.
1,2 L/Z are the only dietary carotenoids able to cross the blood–retinal barrier and accumulate in the fovea to form macular pigment. Macular pigment functions as an antioxidant and as a filter from potentially harmful, short wavelength blue light.
3,4 In comparison with serum measures of L/Z, macular pigment optical density (MPOD) can be measured simply and noninvasively in a clinical setting, and may provide a more direct, stable, and cumulative measure of L/Z levels in the eye over time. Some epidemiologic studies have shown that higher levels of macular pigment may be protective against AMD
5–7 and there is emerging evidence that lower levels of macular pigment are associated with primary open angle glaucoma (POAG).
8–10
Results from two recent studies indicate that greater exposure to L/Z (measured in serum or consumed in dietary supplements) may increase ocular perfusion to the retina and the optic disc.
11,12 This includes a cross-sectional study of 128 elderly Singapore Chinese subjects
11 in which higher serum L/Z was associated with larger central retinal arteriole caliber and smaller retinal venule caliber, consistent with greater ocular perfusion. Thus, L/Z may have applications for preventing vision loss from age-related eye diseases characterized by insufficient retinal blood flow, such as retinal vascular occlusion and glaucomatous optic neuropathy.
13–17 However, these findings concerning measures of L/Z and ocular perfusion require corroboration in an independent cohort.
In this study, we assessed the association between markers of L/Z exposure (including serum L/Z and MPOD) and central retinal vessel caliber in the Carotenoids in Age-Related Eye Disease Study (CAREDS), an observational study of older, predominantly Caucasian women. CAREDS is an ancillary study of postmenopausal U.S. women participating in the Women's Health Initiative (WHI), a multicenter prospective cohort study. We hypothesized that participants in the highest versus lowest tertiles of serum L/Z (at WHI baseline) and MPOD (at CAREDS baseline) would have larger central retinal arteriole caliber and smaller central retinal venule caliber when measured over 15 years later in CAREDS2.
All participants with at least one glaucoma risk factor (i.e., self-reported glaucoma or medication use, intraocular pressure of ≥22 mm Hg, cup to disc ratio of ≥0.6, cup to disc asymmetry of ≥0.2, disc notching, disc hemorrhage, or RNFL thickness <5th percentile average or in any quadrant of either eye) underwent a detailed medical records review, including clinic visit notes, previous OCT imaging and visual fields, to assess for POAG. Participants with possible POAG, but without prior glaucomatous visual fields and no recent visual field testing (≥1 year) were invited to complete Humphrey visual field testing (SITA 24-2 algorithm, Carl Zeiss Meditec, Inc., Jena, Germany) in both eyes. Glaucoma diagnoses (including both manifest and pre-perimetric POAG) were adjudicated via independent review of clinical data and imaging by two fellowship-trained glaucoma specialists (Y.L. and C.T.) masked to participant data on serum L/Z, MPOD, and retinal vessel caliber. Disagreements regarding glaucoma diagnosis were then resolved through repeat review and reaching a consensus between the two glaucoma specialists. For six participants, insufficient data were available to adjudicate the glaucoma outcome. Final glaucoma status was successfully adjudicated for 384 of 390 participants included in the analysis.
In the preliminary analysis, we examined the associations between baseline measures of L status (exposures), as well as retinal vessel calibers (outcomes), and vascular-related covariates using linear and logistic regression with adjustment for age. Next, we investigated whether there was evidence of potential for bias owing to loss to mortality or participation. To investigate the possibility of survival bias in our analysis, participants included in the analysis (n = 390) were compared with CAREDS participants who were excluded from the analysis (n = 1615) in age-adjusted linear models to understand baseline demographic factors, disease conditions, and lifestyle factors that are related to survival and participation in CAREDS2.
Multiple linear regression modeling was then used to investigate the associations between serum L/Z, MPOD, and central retinal vessel calibers, adjusted for age and additional covariates. Linear regression models included an age-adjusted model (model 1) and a covariate-adjusted model (model 2) that includes additional vascular risk factors, including smoking history (never, <7 pack- years, or ≥7 pack-years), self-reported hypertension, self-reported diabetes, systolic blood pressure, total cholesterol, and waist circumference. Covariates were selected for adjustment based on the biological plausibility for confounding and on previously observed associations in the literature.
25
We then stratified our results by MPOD stability between CAREDS baseline and CAREDS2 because we observed that average MPOD increased within individual participants between CAREDS baseline (2001–2004) and CAREDS2 (2016–2019) by an average of 0.14 optical density units. This observation may reflect changes in diet or the increased use of L/Z supplements (unpublished data [Lawler, T, manuscript in preparation]). Stable MPOD was defined as a change in MPOD within 0.10 optical density units between CAREDS baseline and CARED2 follow-up. (Serum L/Z was not measured at CAREDS2, and hence stability of serum L/Z was not assessed.) Statistical significance was set at a threshold of P ≤ .05, for a comparison of tertile 3 versus 1.
All analyses were performed using SAS version 9.4 (SAS Inc. Cary, NC).
The authors thank for the time and energy that the CAREDS2 participants devoted to collecting the data that informed this work.
Supported by National Eye Institute grants EY013018, EY016886 and EY025292, and a supplement to EY025292-01S1 from the Office of Dietary Supplements, as well as by the Molecular and Applied Nutrition Training Program (MANTP) NIH grant T32 DK007665, NIH/NCATS UL1 TR002373 (UW ICTR Basic and Clinical Translational Research Pilot Award), Lions Eye Bank of Wisconsin Gift of Sight Discovery Fund, American Glaucoma Society Mentoring for Advancement of Physician-Scientists (MAPS) Award. This work was also supported in part by an unrestricted grant from Research to Prevent Blindness, Inc., to the UW Madison Department of Ophthalmology and Visual Sciences, and in part by a National Eye Institute Vision Research Core grant (P30 EY016665) to the UW Madison Department of Ophthalmology and Visual Sciences. It is an ancillary study to Women's Health Initiative (WHI). The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C. This work was also supported by a Shapiro Scholarship to Jackson Korger from the University of Wisconsin (UW), School of Medicine and Public Health, Dean's Office, Department of Ophthalmology and Visual Sciences, by the Dan and Ellie Albert Medical Student Scholarship Fund, and by the McPherson Eye Research Institute, and the Wisconsin Academy for Rural Medicine (WARM).
*The Second Carotenoids in Age-Related Eye Disease Study Research Group:
UniversityofWisconsin–Madison: Julie Mares PhD, Barbara Blodi MD, Yao Liu MD MS, Amitha Domalpally MD PhD, Corinne Engelman PhD, Ronald Gangnon PhD, Gloria Sarto MD PhD; OregonHealthSciencesUniversity: Steven Bailey MD, Erin LeBlanc (Kaiser-Permanente); UniversityofIowa: Karen Gehrs MD, Jennifer Robinson MD; MedicalCollegeofWisconsin: Catherine Thuruthumaly MD; Women'sHealthInitiative: Lesley Tinker PhD, RD; UniversityofTexas: D. Max Snodderly PhD; UniversityofGeorgia: Randy Hammond PhD; UniversityatBuffalo: Amy Millen PhD; BrownUniversity: Bill Wooten, PhD; TuftsUniversity: Elizabeth Johnson PhD; CAREDS2ExaminersandClinicalCoordinators: Portland, OR: Jennifer Maykoski, BS; Ann Lundquist, BS; Madison, WI: Chris Smith, BS; Kim Wood, BS; Jennie Perry-Raymond, BS; Iowa City, IA: Heather Stockman, BS; Jean Walshire, BS; Christine Sinkey, BSN.
CAREDS2 Coordinating Center Staff at the UniversityofWisconsin–Madison. Courtney Blomme, MS; Kim Wood, BS; Kristen Hall, BS; Diane Pauk, BS; Esther Mezhibovsky, MS; Scientists: Krista Christensen, PhD; Marine Nalbandyan, MD, PhD.
*Short list of WHI investigators:
Program Office NationalHeart,Lung,andBloodInstitute,Bethesda,Maryland: Jacques Rossouw; Shari Ludlam; Joan McGowan; Leslie Ford; and Nancy Geller.
Clinical Coordinating Center FredHutchinsonCancerResearchCenter,Seattle,WA: Garnet Anderson; Ross Prentice; Andrea LaCroix; and Charles Kooperberg.
Investigators and Academic Centers BrighamandWomen'sHospital,HarvardMedicalSchool,Boston,MA: JoAnn E. Manson; MedStarHealthResearchInstitute/HowardUniversity,Washington,DC: Barbara V. Howard; StanfordPreventionResearchCenter,Stanford,CA: Marcia L. Stefanick; TheOhioStateUniversity,Columbus,OH: Rebecca Jackson; UniversityofArizona,Tucson/Phoenix,AZ: Cynthia A. Thomson; UniversityatBuffalo,Buffalo,NY: Jean Wactawski-Wende; UniversityofFlorida,Gainesville/Jacksonville,FL: Marian Limacher; UniversityofIowa,IowaCity/Davenport,IA: Jennifer Robinson; UniversityofPittsburgh,Pittsburgh,PA: Lewis Kuller; WakeForestUniversitySchoolofMedicine,Winston-Salem,NC: Sally Shumaker; UniversityofNevada,Reno,NV: Robert Brunner.
Women's Health Initiative Memory Study WakeForestUniversitySchoolofMedicine,Winston-Salem,NC: Mark Espeland.
Disclosure: T. Lawler, None; J. Korger, None; Y. Liu, None; Z. Liu, None; J.W. Pak, None; N. Barrett, None; B. Blodi, None; A. Domalpally, None; E. Johnson, None; R. Wallace, None; J. A. Mares, None